Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The group's high margin levels account for strong profits.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 74.13 and 52.16 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC AG29.04%2 885
CELLTRION, INC.--.--%31 908
IQVIA HOLDINGS INC13.49%22 629
LONZA GROUP8.17%21 454
INCYTE CORPORATION-25.97%14 916
SEATTLE GENETICS, INC.31.33%10 764
ALNYLAM PHARMACEUTICALS, IN..-16.62%10 592
QIAGEN19.37%8 471
EXACT SCIENCES CORPORATION28.70%8 135
SAGE THERAPEUTICS INC2.34%7 815
ICON PLC24.96%7 346
ALKERMES PLC-17.71%6 980
PRA HEALTH SCIENCES INC12.57%6 397
CHARLES RIVER LABORATORIES ..13.54%5 770
BIO-TECHNE CORP20.74%5 718
IONIS PHARMACEUTICALS INC-7.55%5 622
More Results
Financials (€)
Sales 2018 353 M
EBIT 2018 48,4 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
P/E ratio 2018 74,13
P/E ratio 2019 52,16
EV / Sales 2018 7,17x
EV / Sales 2019 6,59x
Capitalization 2 462 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart EVOTEC AG
Duration : Period : Day
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Duration : Period : Week
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders